DEVON, Pa., May 09, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of recent operational highlights.
“This quarter, we were very pleased to have surpassed target enrollment in both the STAR 1 and STOP trials for ZYN002 in adult epilepsy and adult osteoarthritis patients, respectively, which we believe indicates strong patient and physician interest in these indications for ZYN002,” said Armando Anido, Chairman and Chief Executive Officer. “We are swiftly advancing our Phase 2 programs for ZYN002 and expect to announce top-line results for the STAR 1 trial first and then the STOP trial in the July/August timeframe, followed by top-line results from the FAB-C study in pediatric Fragile X syndrome patients later in the third quarter. We have also made important progress toward initiating our Phase 1 program for ZYN001, a pro-drug THC patch, which we expect to start by the end of the second quarter of 2017. Momentum across our pipeline continues to build and we remain poised for a transformational 2017.”
